JP2021527706A5 - - Google Patents

Info

Publication number
JP2021527706A5
JP2021527706A5 JP2020571614A JP2020571614A JP2021527706A5 JP 2021527706 A5 JP2021527706 A5 JP 2021527706A5 JP 2020571614 A JP2020571614 A JP 2020571614A JP 2020571614 A JP2020571614 A JP 2020571614A JP 2021527706 A5 JP2021527706 A5 JP 2021527706A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
cdr2
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020571614A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527706A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/037557 external-priority patent/WO2019246003A1/en
Publication of JP2021527706A publication Critical patent/JP2021527706A/ja
Publication of JP2021527706A5 publication Critical patent/JP2021527706A5/ja
Pending legal-status Critical Current

Links

JP2020571614A 2018-06-18 2019-06-17 抗メソテリンコンストラクト及びその使用 Pending JP2021527706A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862686481P 2018-06-18 2018-06-18
US62/686,481 2018-06-18
US201962809496P 2019-02-22 2019-02-22
US62/809,496 2019-02-22
PCT/US2019/037557 WO2019246003A1 (en) 2018-06-18 2019-06-17 Anti-mesothelin constructs and uses thereof

Publications (2)

Publication Number Publication Date
JP2021527706A JP2021527706A (ja) 2021-10-14
JP2021527706A5 true JP2021527706A5 (https=) 2022-06-27

Family

ID=68984126

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020571614A Pending JP2021527706A (ja) 2018-06-18 2019-06-17 抗メソテリンコンストラクト及びその使用
JP2020571720A Pending JP2021529516A (ja) 2018-06-18 2019-06-17 サイトカイン融合タンパク質及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020571720A Pending JP2021529516A (ja) 2018-06-18 2019-06-17 サイトカイン融合タンパク質及びその使用

Country Status (8)

Country Link
US (2) US12215130B2 (https=)
EP (2) EP3806889A4 (https=)
JP (2) JP2021527706A (https=)
KR (2) KR20210021486A (https=)
CN (2) CN112368015B (https=)
CA (2) CA3102036A1 (https=)
TW (2) TW202015721A (https=)
WO (2) WO2019246004A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EP3621994A4 (en) 2017-05-12 2020-12-30 Harpoon Therapeutics, Inc. MESOTHELIN BINDING PROTEINS
EP4029877B1 (en) 2017-08-03 2024-01-17 Amgen Inc. Interleukin-21 muteins and methods of treatment
MX2020003915A (es) 2017-10-13 2020-10-08 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso.
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
TW201930344A (zh) 2018-01-12 2019-08-01 美商安進公司 抗pd-1抗體及治療方法
EP3806889A4 (en) 2018-06-18 2022-07-13 Anwita Biosciences, Inc. CYTOKI FUSION PROTEINS AND USES THEREOF
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
CN113508134B (zh) 2019-02-22 2024-12-03 安维达生物科技公司 白蛋白结合抗体及其用途
CN113710229B (zh) 2019-02-25 2026-01-06 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
AU2020275002A1 (en) 2019-05-14 2021-12-23 Harpoon Therapeutics, Inc. EpCAM binding proteins and methods of use
TW202128961A (zh) 2019-11-20 2021-08-01 美商安維塔生物科學股份有限公司 細胞激素融合蛋白及其醫藥組合物及治療應用
WO2021222150A2 (en) 2020-04-28 2021-11-04 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
CN111518221B (zh) * 2020-07-03 2020-11-27 苏州普乐康医药科技有限公司 一种重组il-15融合蛋白及其应用
TW202221030A (zh) * 2020-07-30 2022-06-01 英商阿法克塔生命科學有限公司 血清白蛋白結合多肽
TW202221019A (zh) * 2020-07-30 2022-06-01 美商安維塔生物科學股份有限公司 介白素-22融合蛋白及其藥物組合物及治療應用
JP2023543266A (ja) * 2020-09-25 2023-10-13 ザ・ユニバーシティ・オブ・シカゴ 抗炎症性サイトカインおよび使用の方法
CN114605539B (zh) * 2020-12-09 2024-01-02 南京融捷康生物科技有限公司 人源化的抗IL-4Rα单域抗体及其应用
KR20230126714A (ko) * 2020-12-18 2023-08-30 바이오아르디스 엘엘씨 메소텔린 결합 분자 및 이의 사용
IL304095A (en) * 2020-12-28 2023-08-01 Zhejiang Nanomab Tech Center Co Ltd Mesothelin binding molecule and its application
CN118206660A (zh) * 2020-12-28 2024-06-18 浙江纳米抗体技术中心有限公司 间皮素结合分子及其应用
WO2022184148A1 (zh) * 2021-03-03 2022-09-09 上海君实生物医药科技股份有限公司 Il-21-抗白蛋白单域抗体融合蛋白药物组合物及其用途
CA3208069A1 (en) * 2021-03-09 2022-09-15 Mary Ellen Molloy Combination therapy with immune cell engaging proteins and immunomodulators
US20240327483A1 (en) * 2021-07-24 2024-10-03 Anwita Biosciences, Inc. Fusion proteins comprising suppression of tumorigenicity 2 or interleukin-33, pharmaceutical compositions, and therapeutic applications
WO2023036246A1 (zh) * 2021-09-09 2023-03-16 深圳市菲鹏生物治疗股份有限公司 一种转基因免疫效应细胞及其应用
CN115838424A (zh) * 2021-09-22 2023-03-24 上海康岱生物医药技术股份有限公司 靶向tigit的单克隆抗体
TW202321296A (zh) 2021-10-06 2023-06-01 美商鏈接免疫療法公司 抗間皮素抗原結合分子及其用途
JP2025505933A (ja) * 2022-01-06 2025-03-05 オリセル セラピューティクス カンパニー リミテッド Mslnを標的とする抗原結合タンパク質及びその使用
JP2025507733A (ja) * 2022-02-28 2025-03-21 ウーシー バイオロジクス アイルランド リミテッド Il-15変異体を含むヘテロ二量体ポリペプチド錯体とその使用
CN116769041A (zh) * 2022-03-10 2023-09-19 合肥瀚科迈博生物技术有限公司 靶向msln和4-1bb的双特异性抗体及其应用
CN115850508A (zh) * 2022-08-19 2023-03-28 浙江卫未生物医药科技有限公司 一种新型il-15超级激动剂融合蛋白
WO2024051796A1 (en) * 2022-09-09 2024-03-14 Wuxi Biologics (Shanghai) Co., Ltd. Albumin binding proteins, fusion proteins and uses thereof
CN120826416A (zh) * 2022-12-02 2025-10-21 杰科生物医药公司 抗间皮素双特异性抗体及其使用方法
CN117186243B (zh) * 2023-07-26 2025-08-19 四川三优康生物技术有限公司 猪白细胞介素15,21和23共表达生物制剂材料及应用
CN117683137B (zh) * 2023-12-04 2024-09-17 江苏省农业科学院 靶向新城疫病毒和h9亚型禽流感病毒的重组双特异性纳米抗体及其制备方法和应用
WO2025143287A1 (ko) * 2023-12-27 2025-07-03 서울대학교산학협력단 메소텔린에 특이적인 항체 및 이의 용도
CN118389554A (zh) * 2024-05-10 2024-07-26 三峡大学 一种提高fgf-21持续表达水平和稳定性的aav重组病毒及其应用
CN120383669B (zh) * 2025-04-24 2025-10-28 广东医科大学 一种重组人长效白细胞介素-22结合蛋白的制备方法及应用

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0092918B1 (en) 1982-04-22 1988-10-19 Imperial Chemical Industries Plc Continuous release formulations
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
AU6430190A (en) 1989-10-10 1991-05-16 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2071867A1 (en) 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
ATE252894T1 (de) 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
WO1997007788A2 (en) 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
US7112324B1 (en) 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
EP1240337B1 (en) 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002335930B2 (en) 2001-03-09 2005-07-28 Morphosys Ag Serum albumin binding moieties
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
WO2004041863A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
TW200607523A (en) * 2004-06-01 2006-03-01 Domantis Ltd Drug compositions, fusions and conjugates
EP1861425B1 (en) * 2005-03-10 2012-05-16 Morphotek, Inc. Anti-mesothelin antibodies
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US8741832B2 (en) 2005-06-10 2014-06-03 Albert Einstein College Of Medicine Of Yeshiva University Pegylated albumin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP4593414B2 (ja) 2005-09-21 2010-12-08 富士通セミコンダクター株式会社 半導体装置の設計装置、設計方法及びプログラム
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
ES2526355T3 (es) * 2007-10-01 2015-01-09 Bristol-Myers Squibb Company Anticuerpos humanos que se adhieren a mesotelina, y usos de los mismos
AR076284A1 (es) * 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
EP2556087A1 (en) 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albumin derivatives and variants
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
US20130225496A1 (en) 2010-11-01 2013-08-29 Novozymes Biopharma Dk A/S Albumin Variants
BR112013014527A2 (pt) * 2010-12-20 2017-03-07 Genentech Inc anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, uso do imunoconjugado, método para tratamento de um indivíduo que tem um câncer positivo para mesotelina, para inibição de proliferação de uma célula positiva para mesotelina, para detecção de mesotelina humana em uma amostra biológica e para detectar um câncer positivo para mesotelina
US9272002B2 (en) * 2011-10-28 2016-03-01 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
US9676849B2 (en) * 2012-01-10 2017-06-13 Biogen Ma Inc. Enhancement of transport of therapeutic molecules across the blood brain barrier
CN104955845B (zh) * 2012-09-27 2018-11-16 美国政府(由卫生和人类服务部的部长所代表) 间皮素抗体和引起有效的抗肿瘤活性的方法
EP2968587A2 (en) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
WO2014182532A1 (en) * 2013-05-07 2014-11-13 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Mesothelin-specific immunocytokine and use thereof
BR112016004355A2 (pt) * 2013-08-30 2017-10-17 Aprilbio Co Ltd constructo de fusão de parte efetora de fab anti-soroalbumina e método de preparação do mesmo
CN105198999A (zh) * 2014-05-27 2015-12-30 上海生物制品研究所有限责任公司 一种融合蛋白、其制备方法及其应用
EP4166148B1 (en) * 2014-06-06 2026-02-18 Memorial Sloan-Kettering Cancer Center Mesothelin-targeted chimeric antigen receptors and uses thereof
US10155025B2 (en) * 2014-07-17 2018-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for inhibiting or reducing transplant rejection by adminstration of interleukin-34
CA2957717C (en) * 2014-08-12 2021-10-19 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
JP6839074B2 (ja) 2014-09-17 2021-03-03 ノバルティス アーゲー 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
AU2015366284B2 (en) * 2014-12-19 2021-07-22 Ablynx N.V. Cysteine linked nanobody dimers
EP3064507A1 (en) * 2015-03-06 2016-09-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
HK1245671A1 (zh) * 2015-05-29 2018-08-31 Armo Biosciences, Inc. 使用白细胞介素-10治疗疾病和病症的方法
WO2017032293A1 (zh) * 2015-08-21 2017-03-02 科济生物医药(上海)有限公司 抗间皮素全人抗体以及靶向间皮素的免疫效应细胞
US11186641B2 (en) 2016-03-17 2021-11-30 Oslo Universitetssykehus Hf Fusion proteins targeting tumour associated macrophages for treating cancer
CN109562143A (zh) * 2016-05-06 2019-04-02 王牧林 白细胞介素组合及其用途
US20180002439A1 (en) * 2016-06-30 2018-01-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-mesothelin antibodies and uses thereof
CN107840891A (zh) * 2016-09-19 2018-03-27 上海吉倍生物技术有限公司 高亲和力的抗msln抗体及其应用
EP3548055A4 (en) 2016-12-02 2020-08-19 University of Southern California SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE
HUE070957T2 (hu) 2017-02-16 2025-07-28 Sonnet Biotherapeutics Inc Albuminkötõ domén fúziós fehérjék
EP3806889A4 (en) * 2018-06-18 2022-07-13 Anwita Biosciences, Inc. CYTOKI FUSION PROTEINS AND USES THEREOF
CN113508134B (zh) * 2019-02-22 2024-12-03 安维达生物科技公司 白蛋白结合抗体及其用途

Similar Documents

Publication Publication Date Title
JP2021527706A5 (https=)
JP7324789B2 (ja) ヒト化抗muc1* 抗体
CN108884160B (zh) 抗ror1抗体
TWI374891B (en) Trimeric soluble antibody and the generating and using method thereof
JP2022093564A5 (https=)
US10865249B2 (en) Antigen-binding polypeptides directed against CD38
JP2025163055A5 (https=)
KR20200104328A (ko) 이중특이적 항원 결합 분자
JP2023509196A5 (https=)
JP2021006044A (ja) 腫瘍壊死因子 (tnf) スーパーファミリー受容体結合分子およびその使用
CN112714768A (zh) 新型抗cd39抗体
JP2010509931A5 (https=)
CA2706425A1 (en) Method for obtaining polypeptide constructs comprising two or more single domain antibodies
JP2023543493A5 (https=)
RS61379B1 (sr) Antitelo na igf-1r i njegova upotreba kao usmerenog nosioca za lečenje kancera
JP2025508009A5 (https=)
JP2023518153A5 (https=)
JP2023531494A5 (https=)
KR20230132544A (ko) 신규한 항-그렘린1 항체
CN115916839A (zh) 抗pdl1×egfr的双特异性抗体
EP4069312A1 (en) Compositions and methods for reducing off-target toxicity of antibody drug conjugates
CN118647629A (zh) 含有TNF-α的免疫缀合物及其相关方法和组合物
CN104271603A (zh) 抗-ErbB2抗体变异体
CN121311510A (zh) 含有TNF-α的免疫缀合物及其相关方法和组合物
KR102681811B1 (ko) Her2에 결합하는 단일 가닥 가변 영역 항체 절편 플랫폼